Medicine and Dentistry
Myelodysplastic Syndrome
100%
Luspatercept
39%
Acute Myeloid Leukemia
36%
International Prognostic Scoring System
30%
Hematopoietic Cell
18%
Cell Transplantation
18%
Anemia
16%
Survival Rate
14%
Quality of Life
12%
Fludarabine
12%
Clinical Trial Design
12%
Whole Body Radiation
12%
Immunology
12%
Secondary Acute Myeloid Leukemia
12%
Acute Leukemia
12%
Hematology
12%
Personalized Medicine
12%
Allogeneic Hematopoietic Stem Cell Transplantation
12%
Conditioning
12%
Busulfan
12%
Allograft
12%
Allogeneic Stem Cell Transplantation
12%
Placebo
10%
Hematopoietic Stem Cell Transplantation
10%
Overall Survival
9%
Adverse Event
8%
Acute Myelogenous Leukemia
8%
Clinical Trial
6%
Long-Term Care
6%
Long Term Survival
6%
Relative Survival
6%
Karyotype
6%
Cumulative Incidence
6%
Biochemistry, Genetics and Molecular Biology
Hematopoietic Stem Cell Transplantation
24%
Genomics
18%
Myeloid
18%
RUNX1
13%
Succinyl-CoA
12%
Erythropoiesis
12%
Synthase
12%
Clinical Trial
12%
Pantothenic Acid
12%
Decision Support System
12%
Coenzyme A
12%
Splicing Factor
12%
Gene Mutation
12%
Allogeneic Hematopoietic Stem Cell Transplantation
12%
Overall Survival
12%
Artificial Intelligence
12%
GATA2
8%
Survival Time
6%
Clinical Genomics
6%
High Risk Population
6%
Life Expectancy
6%
Karyotype
5%
Cell Transplantation
5%
Hematopoietic Cell
5%
Pharmacology, Toxicology and Pharmaceutical Science
Myelodysplastic Syndrome
84%
Luspatercept
36%
Anemia
16%
Secondary Acute Myeloid Leukemia
12%
Fludarabine
12%
Survival Rate
12%
Busulfan
12%
Clinical Trial Design
12%
Acute Myeloid Leukemia
12%
Acute Leukemia
12%
Placebo
10%
Adverse Event
8%
Diseases
6%
Overall Survival
6%
Long Term Survival
6%